1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > United States – Liquid Biopsy Potential Testing Market & Volume Analysis to 2020

United States – Liquid Biopsy Testing Market - Overview

Liquid Biopsy Tests are emerging as a viable alternative to traditional methods for cancer screening. A liquid biopsy is a new type of blood test that has the potential to transform cancer treatment. Using this methodology, physicians avoid the traditional surgical and needle biopsies they use to determine the existence of cancer in patients. In United States Liquid Biopsy market; Screening Test is likely to capture major chunk of the market compared to Monitoring Market. It is anticipated that Liquid Biopsy Testing will be more helpful for monitoring cancer treatment and status after diagnosis than in screening for a cancer that may be years or even decades in the making and not otherwise detectable.

United States – Liquid Biopsy Potential Screening Market Analysis: In the United States liquid biopsy screening market, prostate cancer is the most popular segment. Lung cancer liquid biopsy screening stands at the last spot.

United States – Liquid Biopsy Potential Treatment Monitoring Market Analysis: In the United States liquid biopsy treatment monitoring market, breast cancer is the leading segment. Liver cancer stands at the fifth spot.

Renub Research report titled “United States – Liquid Biopsy Potential Testing Market & Volume Analysis to 2020” provides a comprehensive assessment of the fast–evolving, high–growth of Liquid Biopsy Market. This 79 page report with 41 Figures analyses the United States Liquid Biopsy Test Market and Volume by 5 Top Cancer Segment, Recent developments, Major Deals along with the driving factors and challenges for Liquid Biopsy Market.

The United States Liquid Biopsy Potential Market has been analyzed from two view points

1. United States Liquid Biopsy Potential Screening Market & Test Volume (2015 – 2020)

The Top 5 Cancer Segments covered are:

1. Lung Cancer
2. Breast Cancer
3. Colorectal Cancer
4. Prostate Cancer
5. Liver Cancer


2. United States Liquid Biopsy Potential Treatment Monitoring Market & Test Volume (2015 – 2020)

The Top 6 Cancer Segments covered are:

1. Lung Cancer
2. Breast Cancer
3. Colorectal Cancer
4. Prostate Cancer
5. Liver Cancer
6. Other Cancers


Data Sources

This report is built using data and information sourced from proprietary databases, primary and secondary research and in–house analysis by Renub Research team of industry experts.


Primary sources include industry surveys and telephone interviews with industry experts.

Secondary sources information and data has been collected from various printable and non–printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.

Table Of Contents

United States - Liquid Biopsy Potential Testing Market and Volume Analysis to 2020
Table of Contents

1. Executive Summary

2. United States - Liquid Biopsy Potential Market (2015 - 2020)
2.1 United States - Liquid Biopsy Potential Market
2.2 United States - Liquid Biopsy Screening Potential Market
2.3 United States - Liquid Biopsy Treatment Monitoring Potential Market

3. United States - Liquid Biopsy Potential Test Volume (2015 - 2020)
3.1 United States - Liquid Biopsy Potential Test Volume
3.2 United States - Liquid Biopsy Potential Screening Test Volume
3.3 United States - Liquid Biopsy Potential Treatment Monitoring Test Volume

4. United States - Liquid Biopsy Potential Market Share (2015 - 2020)
4.1 United States - Liquid Biopsy Potential Market Share by Method
4.2 United States - Liquid Biopsy Screening Potential Market Share by Cancer Types
4.3 United States - Liquid Biopsy Treatment Monitoring Potential Market Share by Cancer Types

5. United States - Liquid Biopsy Potential Market and Test Volume by Cancer Types (2015 - 2020)
5.1 United States - Liquid Biopsy Lung Cancer Potential Market and Test Volume
5.1.1 United States - Liquid Biopsy Lung Cancer Potential Market
5.1.2 United States - Liquid Biopsy Lung Cancer Potential Test Volume

5.2 United States - Liquid Biopsy Breast Cancer Potential Market and Test Volume
5.2.1 United States - Liquid Biopsy Breast Cancer Potential Market
5.2.2 United States - Liquid Biopsy Breast Cancer Potential Test Volume

5.3 United States - Liquid Biopsy Colorectal Cancer Potential Market and Test Volume
5.3.1 United States - Liquid Biopsy Colorectal Cancer Potential Market
5.3.2 United States - Liquid Biopsy Colorectal Cancer Potential Test Volume

5.4 United States - Liquid Biopsy Prostate Cancer Potential Market and Test Volume
5.4.1 United States - Liquid Biopsy Prostate Cancer Potential Market
5.4.2 United States - Liquid Biopsy Prostate Cancer Potential Test Volume

5.5 United States - Liquid Biopsy Liver Cancer Potential Market and Test Volume
5.5.1 United States - Liquid Biopsy Liver Cancer Potential Market
5.5.2 United States - Liquid Biopsy Liver Cancer Potential Test Volume

6. United States - Liquid Biopsy Screening Potential Market and Test Volume by Cancer Types (2015 - 2020)
6.1 United States - Liquid Biopsy Lung Cancer Screening Potential Market and Test Volume
6.1.1 United States - Liquid Biopsy Lung Cancer Screening Potential Market
6.1.2 United States - Liquid Biopsy Lung Cancer Screening Potential Test Volume

6.2 United States - Liquid Biopsy Breast Cancer Screening Potential Market and Test Volume
6.2.1 United States - Liquid Biopsy Breast Cancer Screening Potential Market
6.2.2 United States - Liquid Biopsy Breast Cancer Screening Potential Test Volume

6.3 United States - Liquid Biopsy Colorectal Cancer Screening Potential Market and Test Volume
6.3.1 United States - Liquid Biopsy Colorectal Cancer Screening Potential Market
6.3.2 United States - Liquid Biopsy Colorectal Cancer Screening Potential Test Volume

6.4 United States - Liquid Biopsy Prostate Cancer Screening Potential Market and Test Volume
6.4.1 United States - Liquid Biopsy Prostate Cancer Screening Potential Market
6.4.2 United States - Liquid Biopsy Prostate Cancer Screening Potential Test Volume

6.5 United States - Liquid Biopsy Liver Cancer Screening Potential Market and Test Volume
6.5.1 United States - Liquid Biopsy Liver Cancer Screening Potential Market
6.5.2 United States - Liquid Biopsy Liver Cancer Screening Potential Test Volume

7. United States - Liquid Biopsy Treatment Monitoring Potential Market and Test Volume by Cancer Types (2015 - 2020)
7.1 United States - Liquid Biopsy Lung Cancer Treatment Monitoring Potential Market and Test Volume
7.1.1 United States - Liquid Biopsy Lung Cancer Treatment Monitoring Potential Market
7.1.2 United States - Liquid Biopsy Lung Cancer Treatment Monitoring Potential Test Volume

7.2 United States - Liquid Biopsy Breast Cancer Treatment Monitoring Potential Market and Test Volume
7.2.1 United States - Liquid Biopsy Breast Cancer Treatment Monitoring Potential Market
7.2.2 United States - Liquid Biopsy Breast Cancer Treatment Monitoring Potential Test Volume

7.3 United States - Liquid Biopsy Colorectal Cancer Treatment Monitoring Potential Market and Test Volume
7.3.1 United States - Liquid Biopsy Colorectal Cancer Treatment Monitoring Potential Market
7.3.2 United States - Liquid Biopsy Colorectal Cancer Treatment Monitoring Potential Test Volume

7.4 United States - Liquid Biopsy Prostate Cancer Treatment Monitoring Potential Market and Test Volume
7.4.1 United States - Liquid Biopsy Prostate Cancer Treatment Monitoring Potential Market
7.4.2 United States - Liquid Biopsy Prostate Cancer Treatment Monitoring Potential Test Volume

7.5 United States - Liquid Biopsy Liver Cancer Treatment Monitoring Potential Market and Test Volume
7.5.1 United States - Liquid Biopsy Liver Cancer Treatment Monitoring Potential Market
7.5.2 United States - Liquid Biopsy Liver Cancer Treatment Monitoring Potential Test Volume

7.6 United States - Liquid Biopsy Other Cancers Treatment Monitoring Potential Market and Test Volume
7.6.1 United States - Liquid Biopsy Other Cancers Treatment Monitoring Potential Market
7.6.2 United States - Liquid Biopsy Other Cancers Treatment Monitoring Potential Test Volume

8. Liquid Biopsy Market - Recent Development

9. Liquid Biopsy Market - Major Deals Analysis

10. Liquid Biopsy Market - Driving Factors
10.1 Real-Time Evaluation, Convenient and Accuracy
10.2 Increasing Demand for Minimally-Invasive Biopsy Techniques
10.3 Technical Advancement and Personalized Therapies

11. Liquid Biopsy Market - Challenges
11.1 Barriers for Liquid Biopsies
11.1.1 Comparatively Low Concentration of Molecular Biomarkers in Body Fluids
11.1.2 Low Concentration of Target DNA in A Plasma Sample
11.1.3 Proper Handling and Storage of the Samples Critical


List of Figures:

Figure 2 1: United States - Liquid Biopsy Potential Market (Million US$), 2015 - 2020
Figure 2 2: United States - Liquid Biopsy Screening Potential Market (Million US$), 2015 - 2020
Figure 2 3: United States - Liquid Biopsy Treatment Monitoring Potential Market (Million US$), 2015 - 2020

Figure 3 1: United States - Liquid Biopsy Potential Test Volume (Number), 2015 - 2020
Figure 3 2: United States - Liquid Biopsy Potential Screening Test Volume (Number), 2015 - 2020
Figure 3 3: United States - Liquid Biopsy Potential Treatment Monitoring Test Volume (Number), 2015 - 2020

Figure 4 1: United States - Method Wise Liquid Biopsy Potential Market Share (Percent), 2015 - 2020
Figure 4 2: United States - Liquid Biopsy Screening Potential Market Share by Cancer Types (Percent), 2015 - 2020
Figure 4 3: United States - Liquid Biopsy Treatment Monitoring Potential Market Share by Cancer Types (Percent), 2015 - 2020

Figure 5 1: United States - Liquid Biopsy Lung Cancer Potential Market (Million US$), 2015 - 2020
Figure 5 2: United States - Liquid Biopsy Lung Cancer Potential Test Volume (Number), 2015 - 2020
Figure 5 3: United States - Liquid Biopsy Breast Cancer Potential Market (Million US$), 2015 - 2020
Figure 5 4: United States - Liquid Biopsy Breast Cancer Potential Test Volume (Number), 2015 - 2020
Figure 5 5: United States - Liquid Biopsy Colorectal Cancer Potential Market (Million US$), 2015 - 2020
Figure 5 6: United States - Liquid Biopsy Colorectal Cancer Potential Test Volume (Number), 2015 - 2020
Figure 5 7: United States - Liquid Biopsy Prostate Cancer Potential Market (Million US$), 2015 - 2020
Figure 5 8: United States - Liquid Biopsy Prostate Cancer Potential Test Volume (Number), 2015 - 2020
Figure 5 9: United States - Liquid Biopsy Liver Cancer Potential Market (Million US$), 2015 - 2020
Figure 5 10: United States - Liquid Biopsy Liver Cancer Potential Test Volume (Number), 2015 - 2020

Figure 6 1: United States - Liquid Biopsy Lung Cancer Screening Potential Market (Million US$), 2015 - 2020
Figure 6 2: United States - Liquid Biopsy Lung Cancer Screening Potential Test Volume (Number), 2015 - 2020
Figure 6 3: United States - Liquid Biopsy Breast Cancer Screening Potential Market (Million US$), 2015 - 2020
Figure 6 4: United States - Liquid Biopsy Breast Cancer Screening Potential Test Volume (Number), 2015 - 2020
Figure 6 5: United States - Liquid Biopsy Colorectal Cancer Screening Potential Market (Million US$), 2015 - 2020
Figure 6 6: United States - Liquid Biopsy Colorectal Cancer Screening Potential Test Volume (Number), 2015 - 2020
Figure 6 7: United States - Liquid Biopsy Prostate Cancer Screening Potential Market (Million US$), 2015 - 2020
Figure 6 8: United States - Liquid Biopsy Prostate Cancer Screening Potential Test Volume (Number), 2015 - 2020
Figure 6 9: United States - Liquid Biopsy Liver Cancer Screening Potential Market (Million US$), 2015 - 2020
Figure 6 10: United States - Liquid Biopsy Liver Cancer Screening Potential Test Volume (Number), 2015 - 2020

Figure 7 1: United States - Liquid Biopsy Lung Cancer Treatment Monitoring Potential Market (Million US$), 2015 - 2020
Figure 7 2: United States - Liquid Biopsy Lung Cancer Treatment Monitoring Potential Test Volume (Number), 2015 - 2020
Figure 7 3: United States - Liquid Biopsy Breast Cancer Treatment Monitoring Potential Market (Million US$), 2015 - 2020
Figure 7 4: United States - Liquid Biopsy Breast Cancer Treatment Monitoring Potential Test Volume (Number), 2015 - 2020
Figure 7 5: United States - Liquid Biopsy Colorectal Cancer Treatment Monitoring Potential Market (Million US$), 2015 - 2020
Figure 7 6: United States - Liquid Biopsy Colorectal Cancer Treatment Monitoring Potential Test Volume (Number), 2015 - 2020
Figure 7 7: United States - Liquid Biopsy Prostate Cancer Treatment Monitoring Potential Market (Million US$), 2015 - 2020
Figure 7 8: United States - Liquid Biopsy Prostate Cancer Treatment Monitoring Potential Test Volume (Number), 2015 - 2020
Figure 7 9: United States - Liquid Biopsy Liver Cancer Treatment Monitoring Potential Market (Million US$), 2015 - 2020
Figure 7 10: United States - Liquid Biopsy Liver Cancer Treatment Monitoring Potential Test Volume (Number), 2015 - 2020
Figure 7 11: United States - Liquid Biopsy Other Cancers Treatment Monitoring Potential Market (Million US$), 2015 - 2020
Figure 7 12: United States - Liquid Biopsy Other Cancers Treatment Monitoring Potential Test Volume (Number), 2015 - 2020

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 11505
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Lung Cancer: Analytical Tool

Lung Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Ovarian Cancer: Analytical Tool

August 2016 $ 8096

Renal Cancer: Analytical Tool

August 2016 $ 8096

Bladder Cancer: Analytical Tool

August 2016 $ 8096

Brain Cancer: Analytical Tool

August 2016 $ 8096

Breast Cancer: Analytical Tool

August 2016 $ 8096

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.